
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is positioned favorably because the December 2024 acquisition of Greenbrook TMS converted it into a vertically integrated interventional psychiatry platform with 93 company-operated treatment centers, creating scale in a fragmented market and immediate leverage from fixed clinic costs. Its Q2 results showed total revenue of $41.6M, Greenbrook revenue up 17% y/y to $26.9M, gross margin expansion to 51.1%, and first-time positive adjusted EBITDA of $0.3M, all supported by better reimbursement, cleaner claims, and tighter collections. On the NeuroStar side, the shift to a three-pathway commercial model and the AdvancedMD integration should broaden the addressable customer base, while the company’s collaboration with Compass Pathways and SPRAVATO infrastructure could make it an early beneficiary of next-generation therapies in 2027.
Bears say
Neuronetics is pressured by inconsistent commercial execution, the risk of slower procedure volumes, and intensifying competition and pricing pressure in a market that still depends on adoption of its NeuroStar TMS platform. Although it ended Q2 with $25.0M in total cash after $7.6M of ATM proceeds, that liquidity improvement came alongside continued cash usage and a full-year cash flow from operations and investing guide of -$10.5M to -$14.5M, underscoring ongoing funding needs. Its outlook is further weakened by regulatory delays, limited uptake of new products, and higher-than-expected operating expenses, all of which could constrain sales leverage and margin improvement.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares